Biocryst’s galidesivir effective against Zika in macaques

INDICATION: Zika virus

Biocryst’s broad-spectrum viral RNA polymerase inhibitor galidesivir could prevent and treat Zika virus infection. In rhesus macaques, galidesivir treatment starting 1.5 hours after subcutaneous infection reduced Zika virus RNA levels in the plasma, CSF, saliva and urine. Given 24, 48 or 72 hours after infection, galidesivir led to lower plasma and CSF viral RNA levels. When infection was established intravaginally, administration on day 4 or 5 day resulted in undetectable viral RNA levels in plasma and reduced levels in the CSF. ...